Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...